

# Influenza in the time of COVID-19: contributions from three years of the FluCov Project

Marco Del Riccio<sup>1,2</sup>, Bronke Boudewijns<sup>1</sup>, Susanne Heemskerk<sup>1</sup>, Foekje Stelma<sup>1</sup>, Daan van kooten<sup>1</sup>, Caroline Schneeberger<sup>1</sup>, Saverio Caini<sup>1</sup>, Meral Akçay<sup>3</sup>, Erica Dueger<sup>3</sup>, John Paget<sup>1,†</sup>

Affiliations: 1 Netherlands Institute for Health Services Research (Nivel), Utrecht, The Netherlands, 2 Department of Health Sciences, University of Florence, Italy, 3 Sanofi, Lyon, France, † In memoriam of dr. John Paget

## Background


COVID-19 pandemic

Disruption in the global circulation of respiratory viruses

Evolution of influenza viruses' circulation after the pandemic?

## Aim

Document and communicate the impacts of COVID-19 on influenza activity and preventive measures in 25 countries worldwide



## Methods

### Data sources

- WHO FluNet – influenza epi-data
- OurWorldInData – SARS-CoV-2 epi-data
- National reports – Vaccine coverage data
- Scientific literature - evidence on B/Yamagata


### Products

- FluCov Bulletins
- FluCov Influenza Activity Reports
- Interactive FluCov dashboard
- Scientific publications and posters

## Results

### Reports and tools:

- **45 Bulletins + 23 Activity reports** published between June 2021 and August 2024
- **Interactive public dashboard** for user-friendly data access and analysis developed



FluCov Dashboard, Nivel website

### Research outputs:

6 manuscripts prepared, covering 4 topics:

- Impact of SARS-CoV-2 on National Influenza Centers (**2023**)
- Influenza vaccine coverage (**2021 & in preparation**)
- Influenza-susceptible populations (**2023**)
- Potential extinction of B/Yamagata lineage (**2024 & in press**)



Caini et al., Lancet Microbe, 2024

## Conclusion

The FluCov project continues to enrich our understanding of COVID-19's impact on influenza activity and preventive measures. Our ongoing research emphasizes the importance of **continuous surveillance and communication** to address respiratory viruses effectively. We encourage you to **follow our results**, as this project remains vital.



Nivel FluCov Website



Sanofi Library of Congress